2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Michael A. Palese, MD, discusses emerging technologies in benign prostatic hyperplasia.
Michael A. Palese, MD, chair, Department of Urology, Mount Sinai Downtown-Union Square, professor, Department of Urology, Icahn School of Medicine, Mount Sinai, director, Minimally Invasive Surgery, Mount Sinai Health System, discusses emerging technologies in benign prostatic hyperplasia (BPH).
New procedures, such as aquablation, are being evaluated in prostate cancer, Palese says. Aquablation is a minimally invasive surgery that has been approved in Europe and is beginning to gain traction in the United States. Moreover, new procedures involving an iTind device are under investigation that allow the prostate gland to be expanded in that potential adverse effects are avoided, Palese explains. Additionally, the iTind device–based procedure can be performed in an outpatient setting, Palese adds.
Finally, encouraging data have emerging regarding the UroLift device in eligible patients who are interested in avoiding sexual function complications, Palese concludes.